GORE® Launches EXCLUDER® Conformable AAA Endoprosthesis with Active Control System
Gore and Associates recently announced the first use of the FDA-approved Excluder Conformable AAA endoprosthesis with active control system in cases outside of clinical trials. This device was FDA-approved in January 2021, and was supported by findings in a clinical trial.
This device introduces the company’s active control system in AAA treatment. It offers a conformable stent graft; enhanced device positioning; and optional angulation control. This allows physicians to optimize graft conformability and seal to the vessel. Through its ongoing evaluation of device performance and continued data collection, Gore wants to expand approved indications of the device.
To read the article from Endovascular Today, click here.
